Research programme: fatty acid synthase inhibitors - GlaxoSmithKlineAlternative Names: GSK 837149A
Latest Information Update: 06 Sep 2011
At a glance
- Originator GlaxoSmithKline
- Class Small molecules; Sulfonamides; Urea compounds
- Mechanism of Action Fatty acid synthetase complex inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Aug 2011 Early research is ongoing in USA